Migraine Therapeutics - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026 - 2031)

According to Mordor Intelligence, the migraine therapeutics market size expanded from USD 6.58 billion in 2025 to USD 7.02 billion in 2026 and is projected to reach USD 9.74 billion by 2031, advancing at a 6.75% CAGR over 2026-2031.

This report Segments the Industry Into by Therapeutics (Pain-Relieving Medications [Analgesics, and More], Preventive Medications [Anticonvulsants and More]), Route of Administration (Oral, Intravenous, and More), Patient Group (Adults (>=18 Yrs), Adolescents (12-17 Yrs), and Children (<12 Yrs)), and Geography (North America, Europe, and More). The Market Forecasts are Provided in Terms of Value (USD).

Global Migraine Therapeutics Market Trends and Insights

Rapid Penetration of CGRP Antibodies Into First-Line Prevention

The American College of Physicians allowed CGRP antibodies after failure of a single preventive in its 2025 guideline, trimming median time to biologic from 18 months to 5.7 months for commercially insured U.S. adults. Real-world Danish registry tracking shows 52% 12-month adherence for rimegepant compared with 31% for topiramate, largely because gepants avoid cognitive side effects and weight gain. Eptinezumab's quarterly infusion schedule attracts patients intolerant of monthly injections, capturing 18% U.S. biologic share within two years of launch and broadening into pediatrics after October 2024 approval for ages 6-17. Payers accept higher drug costs as emergency-department admissions fall 53% and inpatient stays drop 41% among chronic migraine patients treated with CGRP therapy, delivering USD 4,200 net savings per member annually. Meta-analysis positions erenumab and fremanezumab as superior to flunarizine or valproate by reducing monthly migraine days by 2.4-3.1 versus 1.6-2.0, fueling formulary prioritization.

Oral Gepants Closing the "Triptan-Non-Responder" Gap

Roughly 30-40% of migraine sufferers gain little benefit from triptans because of inadequate efficacy or cardiovascular contraindications, creating headroom for oral gepants that block CGRP receptors without vasoconstriction. The HeAD-US real-world study in 1,856 patients showed similar two-hour pain freedom between gepants and triptans (about 21%) but eight-point higher 24-hour pain relief for gepants, lowering risk of medication overuse. Atogepant became the first oral daily CGRP preventive for chronic migraine in December 2024, offering needle-free convenience that resonates with rural patients lacking refrigeration access. Zavegepant nasal spray delivers pain freedom in 24% within two hours and onset inside 15 minutes, bridging the speed gap between tablets and injections. Rimegepant's dual acute-plus-preventive label simplifies regimens for episodic patients, improving adherence when attack frequency fluctuates.

High Biologic List Prices & Step-Therapy Restrictions

CGRP monoclonal antibodies list at USD 8,100-9,400 annually in the U.S., prompting step-therapy in 72% of commercial and 89% of Medicaid plans. Step protocols postpone CGRP use by 14.3 months and correspond with 38% higher emergency visits, adding USD 11,200 avoidable costs that eclipse the drug price. France assigned ASMR V ("no added benefit") to monoclonals, denying reimbursement and steering neurologists to atogepant or off-label Botox. Absence of biosimilar CGRP antibodies before 2029-2031 preserves price rigidity, ensuring payer resistance will persist beyond the forecast window.

Other drivers and restraints analyzed in the detailed report include:

1. Post-Pandemic Telehealth Adoption Accelerates Accurate Diagnosis & Rx
2. Favorable Reimbursement in EU for Preventive Biologics
3. Safety Concerns Around Ditans' Driving-Impairment Label

For complete list of drivers and restraints, kindly check the Table Of Contents.

Segment Analysis

Pain-relieving medications retained 65.55% of migraine therapeutics market share in 2025, led by triptans and NSAIDs, whereas preventive agents are forecast to grow 9.85% CAGR through 2031, increasing their slice of migraine therapeutics market size. Triptans stay dominant because of generic prices and prescriber familiarity, yet oral gepants capture up to 30-40% of triptan-non-responders, shrinking triptan volumes modestly over the period. Ditans remain niche as their driving label curbs weekday use. CGRP monoclonal antibodies and oral gepants propel preventive uptake after guidelines moved them to second-line status. Botulinum toxin A anchors chronic migraine prevention with long-standing efficacy, although atogepant's chronic label now challenges its near-monopoly. Anticonvulsants and beta-blockers lose ground because of poor tolerability, evidenced by 28-35% 12-month persistence, fueling migration to CGRP options. Meta-analysis shows erenumab and fremanezumab lower monthly migraine days by 2.4-3.1 versus 1.6-2.0 for flunarizine, justifying payer preference for biologics despite cost premium. France's refusal to fund monoclonals but coverage of atogepant illustrates divergent European formularies that influence brand strategy.

Shifts within migraine therapeutics market size mirror clinical innovation tempo. Quarterly eptinezumab infusions entice patients unwilling to self-inject monthly. Oral gepants such as atogepant appeal to chronic patients seeking daily, needle-free dosing. Rimegepant offers dual acute-plus-preventive versatility, easing pill burden for episodic sufferers. Ditans await label refinements to lift mobility restrictions. Ergot alkaloids slide because of vasoconstrictive risk. As biosimilars are unlikely before 2030, originators keep pricing power, while generic triptan suppliers defend share on volume and price.

Complete Report Scope:

• By Drug Class
  • Pain-relieving Medications
    • Analgesics
    • Triptans
    • Ergot Alkaloids
    • Ditans
    • NSAIDs
  • Preventive Medications
    • Blood-pressure-lowering Agents
    • Anticonvulsants
    • Calcitonin Gene-related Peptide (CGRP) Antagonists
    • Botulinum Toxin A
    • Antidepressants
• By Route of Administration
  • Oral
  • Subcutaneous Injection
  • Intranasal
  • Intravenous
  • Transdermal / Other Novel
• By Patient Group
  • Adults (Greater Than 18 yrs)
  • Adolescents (12-17 yrs)
  • Children (Less than 12 yrs)
• By Geography
  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • Germany
    • United Kingdom
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • Rest of Asia-Pacific
  • Middle East and Africa
    • GCC
    • South Africa
    • Rest of Middle East and Africa
  • South America
    • Brazil
    • Argentina
    • Rest of South America

Geography Analysis

North America secured 42.55% of 2025 revenue thanks to high diagnosis rates, broad commercial coverage for CGRP biologics, and dense specialty-clinic networks. Yet step-therapy adds 14.3-month delays and 38% more emergency visits, undercutting optimal outcomes. Canada's fragmented provincial formularies cause inconsistent access; Ontario funds biologics after four migraine days monthly, while Quebec restricts to chronic cases. Mexico's private insurers reimburse CGRP agents for urban elites, but national coverage gaps leave most reliant on triptans.

Europe presents a split landscape. The UK funds atogepant, erenumab, and eptinezumab after two preventive failures, aligning with clinical norms. Germany's positive "additional benefit" rulings give broad reimbursement, whereas Spain's spending caps enforce mid-year pauses. France funds only atogepant among CGRP agents, channeling demand to oral therapy and Botox. Italy's steep discounts keep biologic budgets manageable and volumes rising, offering a blueprint for other cost-sensitive EU states.

Asia-Pacific leads growth at 9.72% CAGR. China's 2024 telemedicine reimbursement adds 180 million potential patients who previously lacked specialist care. India awaits its first CGRP approvals; until then, generic triptans and anticonvulsants dominate. Australia reimburses erenumab and fremanezumab for chronic migraine but not episodic disease, capturing the sickest cohort. South Korea listed rimegepant in 2024, the region's first reimbursed oral gepant, catalyzing adoption momentum. Middle East and Africa confront 4-6-week biologic distribution delays because of cold-chain limitations, sustaining dominance of oral and intranasal drugs. South America's growth focuses on Brazil and Argentina, where private insurance covers CGRP biologics, whereas public systems remain price-constrained.

1. Abbvie
2. Amgen
3. Amneal Pharmaceuticals
4. AstraZeneca
5. Biohaven Pharmaceutical Holding Company Ltd.
6. Bausch Health
7. Bayer
8. Dr. Reddy's Laboratories
9. Eli Lilly and Company
10. GlaxoSmithKline
11. H. Lundbeck
12. Impel Pharmaceuticals Inc.
13. Johnson & Johnson
14. Merck
15. Novartis
16. Pfizer
17. Sun Pharmaceuticals Industries
18. Teva Pharmaceutical Industries
19. Viatris

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support